|
OCRL expression based on
|
| Comparison | Statistical significance |
| Normal-vs-Primary | 2.06279999970249E-07 |
|
Note
Cancer stage information is not available for 2 samples.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Stage1 |
5.47880000034695E-07 |
| Normal-vs-Stage2 |
1.137610E-02 |
| Normal-vs-Stage3 |
6.57209953125459E-10 |
| Normal-vs-Stage4 |
5.69379999815212E-08 |
| Stage1-vs-Stage2 |
1.805700E-02 |
| Stage1-vs-Stage3 |
3.668400E-02 |
| Stage1-vs-Stage4 |
1.343980E-01 |
| Stage2-vs-Stage3 |
1.619120E-03 |
| Stage2-vs-Stage4 |
4.822000E-03 |
| Stage3-vs-Stage4 |
8.752800E-01 |
|
|
Note
Patient race information is not available for 92 samples and one samples from American Indians not included in the above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Caucasian |
2.5115999946479E-08 |
| Normal-vs-AfricanAmerican |
5.255600E-03 |
| Normal-vs-Asian |
3.62630000000363E-05 |
| Caucasian-vs-AfricanAmerican |
1.309350E-01 |
| Caucasian-vs-Asian |
1.498810E-01 |
| AfricanAmerican-vs-Asian |
6.703800E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Male |
2.41830000025089E-07 |
| Normal-vs-Female |
3.45989999983587E-07 |
| Male-vs-Female |
5.514400E-01 |
|
|
Note
Seventeen samples from patient below 21 years not considered in above plot.
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-Age(21-40Yrs) |
1.07130000004396E-06 |
| Normal-vs-Age(41-60Yrs) |
1.64240000044558E-07 |
| Normal-vs-Age(61-80Yrs) |
8.24490000050915E-07 |
| Normal-vs-Age(81-100Yrs) |
3.497000E-03 |
| Age(21-40Yrs)-vs-Age(41-60Yrs) |
4.537600E-01 |
| Age(21-40Yrs)-vs-Age(61-80Yrs) |
9.702800E-01 |
| Age(21-40Yrs)-vs-Age(81-100Yrs) |
2.777000E-01 |
| Age(41-60Yrs)-vs-Age(61-80Yrs) |
5.614000E-01 |
| Age(41-60Yrs)-vs-Age(81-100Yrs) |
3.879000E-01 |
| Age(61-80Yrs)-vs-Age(81-100Yrs) |
3.346200E-01 |
|
|
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Classical-VS-Tall |
4.441100E-04 |
| Classical-VS-Follicular |
4.812400E-04 |
| Classical-VS-Other |
8.430200E-01 |
| Classical-VS-Normal |
2.0035000003471E-07 |
| Tall-VS-Follicular |
6.64799999494647E-08 |
| Tall-VS-Other |
1.219750E-01 |
| Tall-VS-Normal |
1.21859966561999E-10 |
| Follicular-VS-Other |
2.030400E-01 |
| Follicular-VS-Normal |
8.656300E-03 |
| Other-VS-Normal |
2.101600E-02 |
|
|
Note
Cancer in nearby lymph nodes cannot be measured (NX) in 50 samples.
| pathologic_N descriptions |
| N0 | No regional lymph node metastasis |
N1 | Metastases in 1 to 3 axillary lymph nodes |
| N2 | Metastases in 4 to 9 axillary lymph nodes |
N3 | Metastases in 10 or more axillary lymph nodes |
Show statistics |
Hide statistics |
| Comparison |
Statistical significance |
| Normal-vs-N0 |
5.28029999724566E-08 |
| Normal-vs-N1 |
1.48119999598961E-08 |
| N0-vs-N1 |
3.569800E-02 |
|
|
